Novo Nordisk A/S (NVO) EV/FCF Ratio: 43.92x
Is Novo Nordisk A/S’s EV/FCF ratio high or low?
Novo Nordisk A/S's EV/FCF ratio of 43.92x is 12% above its 5-year average of 39.28x, around the middle of its 5-year range (20.25x–91.83x).
As of Wednesday, June 17, 2026. 31.47% above its 12-month average of 33.41x.
NVO EV/FCF Ratio Chart
NVO Average EV/FCF Ratio Chart
NVO Current vs Average EV/FCF Ratio Chart
NVO EV/FCF Ratio Metrics
EV/FCF RATIO
43.92x
EV/FCF RATIO AVG TTM
33.41x
EV/FCF RATIO AVG 3Y
43.13x
EV/FCF RATIO AVG 5Y
36.45x
EV/FCF RATIO AVG 10Y
28.06x
EV/FCF RATIO AVG 15Y
26.73x
EV/FCF RATIO AVG 20Y
26.07x
CURRENT VS TTM AVG
+31.47%
CURRENT VS 3Y AVG
+1.83%
CURRENT VS 5Y AVG
+20.49%
CURRENT VS 10Y AVG
+56.52%
CURRENT VS 15Y AVG
+64.32%
CURRENT VS 20Y AVG
+68.49%
NVO Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.39B | 43.92x | 33.41x | 43.13x | 36.45x |
| Amgen Inc. (AMGN)vs › | $187.59B | 27.28x | 22.47x | 24.98x | 22.52x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 32.04x | 35.79x | 34.56x | 34.77x |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 17.02x | 18.53x | 16.06x | 14.52x |
| Abbott Laboratories (ABT)vs › | $157.84B | 25.15x | 30.82x | 34.90x | 31.02x |
| Pfizer Inc. (PFE)vs › | $148.41B | 22.35x | 19.82x | 27.37x | 21.38x |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 52.23x | 78.91x | 160.14x | 125.07x |
| Danaher Corporation (DHR)vs › | $128.06B | 26.79x | 31.87x | 32.32x | 30.49x |
| CVS Health Corporation (CVS)vs › | $127.73B | 26.73x | 27.83x | 27.04x | 21.16x |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $116.49B | 30.76x | 32.22x | 28.40x | 25.11x |
Cash Flow Valuation Comparison
EV/FCF
43.9x
P/FCF
39.9x
FCF Yield
2.50%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Novo Nordisk A/S EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The EV/FCF ratio for NVO stock is 43.92x.
- Is Novo Nordisk A/S's EV/FCF ratio high or low?
- Novo Nordisk A/S's EV/FCF ratio of 43.92x is 12% above its 5-year average of 39.28x, around the middle of its 5-year range (20.25x–91.83x).
- What is the TTM average EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The TTM average EV/FCF ratio for NVO stock is 33.41x.
- What is the 3Y average EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The 3Y average EV/FCF ratio for NVO stock is 43.13x.
- What is the 5Y average EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The 5Y average EV/FCF ratio for NVO stock is 36.45x.
- What is the 10Y average EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The 10Y average EV/FCF ratio for NVO stock is 28.06x.
- What is the 15Y average EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The 15Y average EV/FCF ratio for NVO stock is 26.73x.
- What is the 20Y average EV/FCF ratio for Novo Nordisk A/S (NVO)?
- The 20Y average EV/FCF ratio for NVO stock is 26.07x.
Novo Nordisk A/S EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-17 | 43.92x |
| 2026-06-16 | 43.94x |
| 2026-06-15 | 44.28x |
| 2026-06-12 | 44.25x |
| 2026-06-11 | 44.32x |
| 2026-06-10 | 43.27x |
| 2026-06-09 | 42.70x |
| 2026-06-08 | 41.62x |
| 2026-06-05 | 43.40x |
| 2026-06-04 | 44.13x |
| 2026-06-03 | 42.52x |
| 2026-06-02 | 43.37x |
| 2026-06-01 | 44.42x |
| 2026-05-29 | 45.81x |
| 2026-05-28 | 45.74x |
| 2026-05-27 | 44.86x |
| 2026-05-26 | 44.53x |
| 2026-05-22 | 45.24x |
| 2026-05-21 | 44.72x |
| 2026-05-20 | 45.34x |
| 2026-05-19 | 44.61x |
| 2026-05-18 | 44.61x |
| 2026-05-15 | 45.04x |
| 2026-05-14 | 46.01x |
| 2026-05-13 | 47.18x |
| 2026-05-12 | 47.11x |
| 2026-05-11 | 46.56x |
| 2026-05-08 | 46.26x |
| 2026-05-07 | 46.01x |
| 2026-05-06 | 45.97x |
| 2026-05-05 | 48.63x |
| 2026-05-04 | 48.15x |
| 2026-05-01 | 47.64x |
| 2026-04-30 | 45.98x |
| 2026-04-29 | 44.05x |
| 2026-04-28 | 44.93x |
| 2026-04-27 | 44.96x |
| 2026-04-24 | 44.93x |
| 2026-04-23 | 42.27x |
| 2026-04-22 | 42.91x |
| 2026-04-21 | 43.18x |
| 2026-04-20 | 44.22x |
| 2026-04-17 | 44.28x |
| 2026-04-16 | 44.69x |
| 2026-04-15 | 44.57x |
| 2026-04-14 | 43.08x |
| 2026-04-13 | 41.73x |
| 2026-04-10 | 41.27x |
| 2026-04-09 | 41.19x |
| 2026-04-08 | 41.36x |
| 2026-04-07 | 40.66x |
| 2026-04-06 | 40.42x |
| 2026-04-02 | 40.73x |
| 2026-04-01 | 40.23x |
| 2026-03-31 | 40.50x |
| 2026-03-30 | 39.04x |
| 2026-03-27 | 39.79x |
| 2026-03-26 | 40.15x |
| 2026-03-25 | 40.08x |
| 2026-03-24 | 40.64x |
| 2026-03-23 | 40.57x |
| 2026-03-20 | 40.28x |
| 2026-03-19 | 40.83x |
| 2026-03-18 | 41.20x |
| 2026-03-17 | 42.18x |
| 2026-03-16 | 42.33x |
| 2026-03-13 | 41.71x |
| 2026-03-12 | 41.77x |
| 2026-03-11 | 42.58x |
| 2026-03-10 | 42.47x |
| 2026-03-09 | 43.54x |
| 2026-03-06 | 42.33x |
| 2026-03-05 | 42.83x |
| 2026-03-04 | 42.25x |
| 2026-03-03 | 40.41x |
| 2026-03-02 | 41.51x |
| 2026-02-27 | 41.20x |
| 2026-02-26 | 41.37x |
| 2026-02-25 | 41.91x |
| 2026-02-24 | 42.34x |
| 2026-02-23 | 43.39x |
| 2026-02-20 | 51.19x |
| 2026-02-19 | 52.22x |
| 2026-02-18 | 53.00x |
| 2026-02-17 | 53.14x |
| 2026-02-13 | 53.34x |
| 2026-02-12 | 52.70x |
| 2026-02-11 | 52.51x |
| 2026-02-10 | 52.89x |
| 2026-02-09 | 53.14x |
| 2026-02-06 | 51.41x |
| 2026-02-05 | 47.10x |
| 2026-02-04 | 50.96x |
| 2026-02-03 | 54.07x |
| 2026-02-02 | 28.62x |
| 2026-01-30 | 28.86x |
| 2026-01-29 | 28.81x |
| 2026-01-28 | 29.28x |
| 2026-01-27 | 30.47x |
| 2026-01-26 | 30.98x |
| 2026-01-23 | 30.18x |
| 2026-01-22 | 30.16x |
| 2026-01-21 | 28.80x |
| 2026-01-20 | 29.44x |
| 2026-01-16 | 30.21x |
| 2026-01-15 | 27.78x |
| 2026-01-14 | 28.61x |
| 2026-01-13 | 28.95x |
| 2026-01-12 | 29.06x |
| 2026-01-09 | 28.57x |
| 2026-01-08 | 27.88x |
| 2026-01-07 | 27.52x |
| 2026-01-06 | 27.38x |
| 2026-01-05 | 26.84x |
| 2026-01-02 | 25.57x |
| 2025-12-31 | 24.87x |
| 2025-12-30 | 25.03x |
| 2025-12-29 | 25.14x |
| 2025-12-26 | 25.58x |
| 2025-12-24 | 25.65x |
| 2025-12-23 | 25.21x |
| 2025-12-22 | 23.57x |
| 2025-12-19 | 23.57x |
| 2025-12-18 | 23.34x |
| 2025-12-17 | 23.42x |
| 2025-12-16 | 23.97x |
| 2025-12-15 | 24.63x |
| 2025-12-12 | 24.54x |
| 2025-12-11 | 24.59x |
| 2025-12-10 | 24.01x |
| 2025-12-09 | 22.76x |
| 2025-12-08 | 22.95x |
| 2025-12-05 | 23.46x |
| 2025-12-04 | 23.52x |
| 2025-12-03 | 23.32x |
| 2025-12-02 | 23.26x |
| 2025-12-01 | 23.73x |
| 2025-11-28 | 24.15x |
| 2025-11-26 | 23.86x |
| 2025-11-25 | 23.09x |
| 2025-11-24 | 22.11x |
| 2025-11-21 | 23.35x |
| 2025-11-20 | 23.34x |
| 2025-11-19 | 23.99x |
| 2025-11-18 | 23.31x |
| 2025-11-17 | 23.74x |
| 2025-11-14 | 23.65x |
| 2025-11-13 | 24.07x |
| 2025-11-12 | 24.58x |
| 2025-11-11 | 24.06x |
| 2025-11-10 | 22.56x |
| 2025-11-07 | 22.44x |
| 2025-11-06 | 22.83x |
| 2025-11-05 | 23.74x |
| 2025-11-04 | 24.18x |
| 2025-11-03 | 24.59x |
| 2025-10-31 | 24.75x |
| 2025-10-30 | 25.03x |
| 2025-10-29 | 25.66x |
| 2025-10-28 | 25.98x |
| 2025-10-27 | 26.38x |
| 2025-10-24 | 26.41x |
| 2025-10-23 | 26.54x |
| 2025-10-22 | 26.61x |
| 2025-10-21 | 27.27x |
| 2025-10-20 | 27.73x |
| 2025-10-17 | 27.08x |
| 2025-10-16 | 27.89x |
| 2025-10-15 | 28.19x |
| 2025-10-14 | 28.16x |
| 2025-10-13 | 28.56x |
| 2025-10-10 | 28.29x |
| 2025-10-09 | 29.12x |
| 2025-10-08 | 29.56x |
| 2025-10-07 | 29.28x |
| 2025-10-06 | 29.57x |
| 2025-10-03 | 29.57x |
| 2025-10-02 | 29.14x |
| 2025-10-01 | 29.35x |
| 2025-09-30 | 27.61x |
| 2025-09-29 | 27.61x |
| 2025-09-26 | 27.66x |
| 2025-09-25 | 27.87x |
| 2025-09-24 | 29.14x |
| 2025-09-23 | 29.52x |
| 2025-09-22 | 30.08x |
| 2025-09-19 | 30.40x |
| 2025-09-18 | 30.62x |
| 2025-09-17 | 28.89x |
| 2025-09-16 | 28.42x |
| 2025-09-15 | 27.67x |
| 2025-09-12 | 27.31x |
| 2025-09-11 | 27.04x |
| 2025-09-10 | 27.08x |
| 2025-09-09 | 27.04x |
| 2025-09-08 | 27.03x |
| 2025-09-05 | 27.48x |
| 2025-09-04 | 27.91x |
| 2025-09-03 | 28.20x |
| 2025-09-02 | 28.03x |
| 2025-08-29 | 28.07x |
| 2025-08-28 | 27.90x |
| 2025-08-27 | 28.06x |
| 2025-08-26 | 27.54x |
| 2025-08-25 | 28.01x |
| 2025-08-22 | 28.31x |
| 2025-08-21 | 27.59x |
| 2025-08-20 | 27.04x |
| 2025-08-19 | 27.27x |
| 2025-08-18 | 26.78x |
| 2025-08-15 | 26.15x |
| 2025-08-14 | 25.46x |
| 2025-08-13 | 25.44x |
| 2025-08-12 | 24.91x |
| 2025-08-11 | 24.95x |
| 2025-08-08 | 25.52x |
| 2025-08-07 | 24.42x |
| 2025-08-06 | 22.82x |
| 2025-08-05 | 20.32x |
| 2025-08-04 | 20.96x |
| 2025-08-01 | 20.71x |
| 2025-07-31 | 20.25x |
| 2025-07-30 | 21.46x |
| 2025-07-29 | 23.06x |
| 2025-07-28 | 29.20x |
| 2025-07-25 | 30.30x |
| 2025-07-24 | 29.90x |
| 2025-07-23 | 29.62x |
| 2025-07-22 | 28.29x |
| 2025-07-21 | 27.53x |
| 2025-07-18 | 27.28x |
| 2025-07-17 | 27.68x |
| 2025-07-16 | 28.40x |
| 2025-07-15 | 28.47x |
| 2025-07-14 | 29.17x |
| 2025-07-11 | 29.17x |
| 2025-07-10 | 30.02x |
| 2025-07-09 | 29.48x |
| 2025-07-08 | 29.46x |
| 2025-07-07 | 29.33x |
| 2025-07-03 | 29.27x |
| 2025-07-02 | 29.53x |
| 2025-07-01 | 29.53x |
| 2025-06-30 | 29.20x |
| 2025-06-27 | 29.00x |
| 2025-06-26 | 28.67x |
| 2025-06-25 | 28.52x |
| 2025-06-24 | 29.90x |
| 2025-06-23 | 29.49x |
| 2025-06-20 | 31.14x |
| 2025-06-18 | 31.24x |
| 2025-06-17 | 31.37x |
| 2025-06-16 | 32.47x |
| 2025-06-13 | 33.61x |
| 2025-06-12 | 34.11x |
| 2025-06-11 | 33.16x |
| 2025-06-10 | 33.41x |
| 2025-06-09 | 31.83x |
| 2025-06-06 | 31.49x |
| 2025-06-05 | 30.68x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar